Sign in
4

Changes in Ownership

Amylyx Pharmaceuticals, Inc. Filed Acc 0001193125-26-017057

Co-Chief Executive Officer sold 138,167 shares at an average $13.59 ($1,878,094)

  • Co-Chief Executive Officer acquired 200,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Cohen Joshua B Co-Chief Executive Officer 2026-01-15 Option exercise +197,182 $7.57 $1,492,668 3,514,814 D: show line 1 in the form
Cohen Joshua B Co-Chief Executive Officer 2026-01-15 Sale −136,193 $13.59 $1,850,795 3,378,621 D: show line 2 in the form
Cohen Joshua B Co-Chief Executive Officer 2026-01-16 Option exercise +2,818 $7.57 $21,332 3,381,439 D: show line 3 in the form
Cohen Joshua B Co-Chief Executive Officer 2026-01-16 Sale −1,974 $13.83 $27,299 3,379,465 D: show line 4 in the form
Open-market sales · 138,167 sh · avg $13.59 · $1,878,094

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
Cohen Joshua B Co-Chief Executive Officer 2026-01-15 Option exercise · Stock Option (Right to Buy) −197,182 2,818 D: show line 5 in the form
Cohen Joshua B Co-Chief Executive Officer 2026-01-16 Option exercise · Stock Option (Right to Buy) −2,818 0 D: show line 6 in the form
Loading xslF345X05/ownership.xml…